Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/81146
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)
Author: Nathanson, K.
Martin, A.
Wubbenhorst, B.
Greshock, J.
Letrero, R.
D'Andrea, K.
O'Day, S.
Infante, J.
Falchook, G.
Arkenau, T.
Millward, M.
Brown, M.
Pavlick, A.
Davies, M.
Ma, B.
Gagnon, R.
Curtis, M.
Lebowitz, P.
Kefford, R.
Long, G.
Citation: Clinical Cancer Research, 2013; 19(17):4868-4878
Publisher: Amer Assoc Cancer Research
Issue Date: 2013
ISSN: 1078-0432
1557-3265
Statement of
Responsibility: 
Katherine L. Nathanson, Anne-Marie Martin, Bradley Wubbenhorst, Joel Greshock, Richard Letrero, Kurt D'Andrea, Steven O'Day, Jeffrey R. Infante, Gerald S. Falchook, Hendrik-Tobias Arkenau, Michael Millward, Michael P. Brown, Anna Pavlick, Michael A. Davies, Bo Ma, Robert Gagnon, Martin Curtis, Peter F. Lebowitz, Richard Kefford, and Georgina V. Long
Abstract: <h4>Purpose</h4>Dabrafenib is a selective inhibitor of V600-mutant BRAF kinase, which recently showed improved progression-free survival (PFS) as compared with dacarbazine, in metastatic melanoma patients. This study examined potential genetic markers associated with response and PFS in the phase I study of dabrafenib.<h4>Experimental design</h4>Baseline (pretreatment or archival) melanoma samples were evaluated in 41 patients using a custom genotyping melanoma-specific assay, sequencing of PTEN, and copy number analysis using multiplex ligation amplification and array-based comparative genomic hybridization. Nine patients had on-treatment and/or progression samples available.<h4>Results</h4>All baseline patient samples had BRAF(V600E/K) confirmed. Baseline PTEN loss/mutation was not associated with best overall response to dabrafenib, but it showed a trend for shorter median PFS [18.3 (95% confidence interval, CI, 9.1-24.3) vs. 32.1 weeks (95% CI, 24.1-33), P=0.059]. Higher copy number of CCND1 (P=0.009) and lower copy number of CDKN2A (P=0.012) at baseline were significantly associated with decreased PFS. Although no melanomas had high-level amplification of BRAF, the two patients with progressive disease as their best response had BRAF copy gain in their tumors.<h4>Conclusions</h4>Copy number changes in CDKN2A, CCND1, and mutation/copy number changes in PTEN correlated with the duration of PFS in patients treated with dabrafenib. The results suggest that these markers should be considered in the design and interpretation of future trials with selective BRAF inhibitors in advanced melanoma patients.
Keywords: Humans; Melanoma; Disease Progression; Oximes; Imidazoles; Proto-Oncogene Proteins B-raf; Cyclin D1; Neoplasm Staging; Disease-Free Survival; Mutation; Cyclin-Dependent Kinase Inhibitor p16; PTEN Phosphohydrolase; Comparative Genomic Hybridization; DNA Copy Number Variations
Rights: ©2013 AACR.
RMID: 0020131340
DOI: 10.1158/1078-0432.CCR-13-0827
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.